Instruct the patient to begin taking drospirenone, ethinyl estradiol and levomefolate calcium tablets and levomefolate calcium tablets either on the first day of her menstrual period (Day 1 Start) or on the first Sunday after the onset of her menstrual period (Sunday Start).ĭuring the first cycle of drospirenone, ethinyl estradiol and levomefolate calcium tablets and levomefolate calcium tablets use, instruct the patient to take one pink drospirenone, ethinyl estradiol and levomefolate calcium tablet and levomefolate calcium tablet daily, beginning on Day 1 of her menstrual cycle. ![]() In making the diagnosis, care should be taken to rule out other cyclical mood disorders.ĭrospirenone, ethinyl estradiol and levomefolate calcium tablets and levomefolate calcium tablets has not been evaluated for the treatment of premenstrual syndrome (PMS).Ģ.2 How to Start Drospirenone, Ethinyl Estradiol and Levomefolate Calcium Tablets and Levomefolate Calcium Tablets Diagnosis is made by healthcare providers according to DSM-IV criteria, with symptomatology assessed prospectively over at least two menstrual cycles. In this disorder, these symptoms occur regularly during the luteal phase and remit within a few days following onset of menses the disturbance markedly interferes with work or school, or with usual social activities and relationships with others. Physical symptoms associated with PMDD include breast tenderness, headache, joint and muscle pain, bloating and weight gain. Other features include decreased interest in usual activities, difficulty concentrating, lack of energy, change in appetite or sleep, and feeling out of control. The essential features of PMDD according to the Diagnostic and Statistical Manual-4th edition (DSM-IV) include markedly depressed mood, anxiety or tension, affective lability, and persistent anger or irritability. The effectiveness of drospirenone, ethinyl estradiol and levomefolate calcium tablets and levomefolate calcium tablets for PMDD when used for more than three menstrual cycles has not been evaluated. ( 5.10)ġ.2 Premenstrual Dysphoric Disorder (PMDD)ĭrospirenone, ethinyl estradiol and levomefolate calcium tablets and levomefolate calcium tablets are also indicated for the treatment of symptoms of premenstrual dysphoric disorder (PMDD) in females of reproductive potential who choose to use an oral contraceptive as their method of contraception. Uterine bleeding: Evaluate irregular bleeding or amenorrhea.Headache: Evaluate significant change in headaches and discontinue drospirenone, ethinyl estradiol and levomefolate calcium tablets and levomefolate calcium tablets if indicated.Consider an alternate contraceptive method for women with uncontrolled dyslipidemia. Carbohydrate and lipid metabolic effects: Monitor prediabetic and diabetic women taking drospirenone, ethinyl estradiol and levomefolate calcium tablets and levomefolate calcium tablets.High blood pressure: Do not prescribe drospirenone, ethinyl estradiol and levomefolate calcium tablets and levomefolate calcium tablets for women with uncontrolled hypertension or hypertension with vascular disease.Liver disease: Discontinue Drospirenone, ethinyl estradiol and levomefolate calcium tablets and levomefolate calcium tablets if jaundice occurs. ![]() Check serum potassium concentration during the first treatment cycle in women on long-term treatment with medications that may increase serum potassium concentration. Do not use in patients predisposed to hyperkalemia.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |